Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days

Arbutus Biopharma Corporation

Contributing Author

Recent Articles by Arbutus Biopharma Corporation

Aug-24	Arbutus Commences US$230 Million Modified "Dutch Auction" Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share ABUS GlobeNewswire
Aug-21	Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified "Dutch Auction" Tender Offer ABUS +9.22% GlobeNewswire
Aug-12	Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update ABUS GlobeNewswire
Jul-16	Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders ABUS GlobeNewswire
May-13	Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update ABUS GlobeNewswire
Apr-15	Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B ABUS GlobeNewswire
Mar-23	Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update ABUS GlobeNewswire
Mar-03	Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna ABUS GlobeNewswire
Nov-13	Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update ABUS -5.79% GlobeNewswire
Oct-07	Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting 2025 ABUS GlobeNewswire
Aug-06	Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update ABUS GlobeNewswire
Jun-25	Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus ABUS GlobeNewswire
May-14	Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update ABUS GlobeNewswire
May-07	Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 ABUS GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)